Advertisement

Nutrafoods

, Volume 13, Issue 1, pp 35–43 | Cite as

Effect of licorice flavonoid oil on visceral fat in obese subjects in the United States

A randomized, double-blind, placebo-controlled study
  • Yuji Tominaga
  • Mitsuaki Kitano
  • Tatsumasa Mae
  • Sachie Kakimoto
  • Kaku NakagawaEmail author
Original Research

Abstract

Abdominal obesity, or accumulation of visceral fat, is mainly associated with the onset of metabolic syndrome. Licorice flavonoid oil (LFO) consisting of licorice hydrophobic polyphenols in mediumchain triglycerides (MCT) is a new functional food ingredient effective in preventing metabolic syndrome. We have demonstrated significant effects of LFO on reduction of total body fat and visceral fat together with body weight in overweight Japanese subjects. Obesity is a more serious problem in Western countries such as Europe and the United States compared to Japan. We hypothesized that LFO could also work for abdominally obese people in Western countries. We therefore tested the effects of 300 mg LFO concentrate solution taken once daily with evening meals for up to 12 weeks in obese adult male and female subjects in the United States. Results showed that visceral fat, as measured by an abdominal CT scan, waist circumference measurements and waist-to-hip ratio significantly decreased in subjects in the LFO group compared to the placebo group at Week 12. The side-effect profile of LFO was indistinguishable from placebo. Moreover, no adverse trends or toxicologically meaningful differences in haematology and chemistry test results, vital signs or physical examinations were observed that were attributable to LFO. These results indicate that LFO is a safe food ingredient for preventing metabolic syndrome not only in Japan but also in Western countries such as Europe and the United States.

Keywords

licorice flavonoid Glycyrrhiza glabra L. metabolic syndrome visceral fat, total body fat abdominal fat 

Abbreviations

LFO

licorice flavonoid oil

MCT

medium-chain triglycerides

AE

adverse event

BMI

body mass index

BMR

basal metabolic rate

CT

computed tomography

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome: a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480CrossRefGoogle Scholar
  2. 2.
    Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J (2005) The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12:295–300CrossRefGoogle Scholar
  3. 3.
    Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689CrossRefGoogle Scholar
  4. 4.
    Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults. JAMA 287:356–359CrossRefGoogle Scholar
  5. 5.
    Matsuzawa Y (2008) The role of fat topology in the risk of disease. Int J Obes 32:S83–92CrossRefGoogle Scholar
  6. 6.
    Matsuzawa Y (2006) The metabolic syndrome and adipocytokines. FEBS Lett 580:2917–2921CrossRefGoogle Scholar
  7. 7.
    Semenkovih CF (2006) Insulin resistance and atherosclerosis. J Clin Invest 116:1813–1822CrossRefGoogle Scholar
  8. 8.
    Nakagawa K, Kishida H, Arai N, Nishiyama T, Mae T (2004) Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-Ay mice. Biol Pharm Bull 27:1775–1778CrossRefGoogle Scholar
  9. 9.
    Aoki F, Honda S, Kishida H, Kitano M, Arai N, Tanaka H, Yokota S, Nakagawa K, Asakura T, Nakai Y, Mae T (2007) Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice. Biosci Biotechnol Biochem 71:206–214CrossRefGoogle Scholar
  10. 10.
    Nakagawa K, Kitano M, Kishida H, Hidaka T, Nabae K, Kawabe M, Hosoe K (2008) 90-Day repeated-dose toxicity study of licorice flavonoid oil (LFO) in rats. Food Chem Toxicol 46:2349–2357CrossRefGoogle Scholar
  11. 11.
    Nakagawa K, Hidaka T, Kitano M, Asakura M, Kamigaito T, Noguchi T, Hosoe K (2008) Genotoxicity studies on licorice flavonoid oil (LFO). Food Chem Toxicol 46:2525–2532CrossRefGoogle Scholar
  12. 12.
    Nakagawa K, Hosoe K, Hidaka T, Nabae K, Kawabe M, Kitano M (2010) Inhibition by licorice flavonoid oil of glutathione S-transferase-positive foci in the medium-term rat hepatocarcinogenesis bioassay. Nutr Res 30:74–81CrossRefGoogle Scholar
  13. 13.
    Aoki F, Nakagawa K, Kitano M, Ikematsu H, Nakamura K, Yokota S, Tominaga Y, Arai N, Mae T (2007) Clinical safety of licorice flavonoid oil (LFO) and pharmacokinetics of glabridin in healthy humans. J Am Coll Nutr 26:209–218CrossRefGoogle Scholar
  14. 14.
    Tominaga Y, mae T, Kitano M, Sakamoto Y, Ikematsu H, Nakagawa K (2006) Licorice flavonoid oil effects body weight loss by reduction of body fat mass in overweight subjects. J Health Sci 52:672–683CrossRefGoogle Scholar
  15. 15.
    Tominaga Y, Nakagawa K, Mae T, Kitano M, Yokota S, Arai T, Ikematsu H, Inoue S (2009) Licorice flavonoid oil reduces total body fat and visceral fat in overweight subjects: a randomized, double-blind, placebo-controlled study. Obes Res Clin Pract 3:169–178CrossRefGoogle Scholar
  16. 16.
    Harris JA, Benedict FG (1919) A biometric study of basal metabolism in man. Carnegie Institution of Washington, WashingtonGoogle Scholar
  17. 17.
    U.S. Department of Health and Human Services, PHS (1996) NHANES III Anthropometric Procedures Video. U.S. Government Printing Office Stock Number 017-022-01335-5. U.S. GPO, Public Health Service, Washington, D.C.Google Scholar
  18. 18.
    World Health Organization Media centre (2013) Obesity and overweight. Fact sheet no. 311, updated March 2013. http://who.int/mediacentre/factsheets/fs311/en/index.html Google Scholar
  19. 19.
    The Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity (2002) New criteria for ‘obesity disease’ in Japan. Circ J 66:987–992CrossRefGoogle Scholar
  20. 20.
    Seidell JC (2002) Prevalence and time trends of obesity in Europe. J Endocrinol Invest 25:816–822CrossRefGoogle Scholar
  21. 21.
    Sanches FMR, Avesani CM, Kamimura MA, Lemos MM, Axelsson J, Vasselai P, Draibe SA, Cuppari L (2008) Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis 52:66–73CrossRefGoogle Scholar
  22. 22.
    Fujioka S, Matsuzawa Y, Tokunaga K, Keno Y, Kobatake T, Tarui S (1991) Treatment of visceral fat obesity. Int J Obes 15:59–65Google Scholar
  23. 23.
    Shimomura I, Tokunaga K, Kotani K, Keno Y, Yanase-Fujiwara M, Kanosue K, Jiao S, Funahashi T, Kobatake T, Yamamoto T, Matsuzawa Y (1993) Marked reduction of acyl-CoA synthetase activity and mRNA in intra-abdominal visceral fat by physical exercise. Am J Physiol 265:E44–50Google Scholar
  24. 24.
    Kamisoyama H, Honda K, Tominaga Y, Yokota S, Hasegawa S (2008) Investigation of the anti-obesity action of licorice flavonoid oil in diet-induced obese rats. Biosci Biotechnol Biochem 72:3225–3231CrossRefGoogle Scholar

Copyright information

© CEC editore - Springer-Verlag Italia 2014

Authors and Affiliations

  • Yuji Tominaga
    • 1
  • Mitsuaki Kitano
    • 1
  • Tatsumasa Mae
    • 2
  • Sachie Kakimoto
    • 2
  • Kaku Nakagawa
    • 2
    Email author
  1. 1.Pharmacology & Toxicology Laboratory Frontier Biochemical and Medical Research LaboratoriesKaneka CorporationHyogoJapan
  2. 2.QOL DivisionKaneka CorporationOsakaJapan

Personalised recommendations